D ecompensated liver cirrhosis, often due to complications of clinically significant portal hypertension, (1) might end in acute-onchronic liver failure (ACLF), which is associated with elevated systemic inflammation (2) and high mortality. (3) Complications of portal hypertension can be successfully treated by implantation of a transjugular intrahepatic portosystemic shunt (TIPS). (4) (5) (6) TIPS leads to immediate decompression in the portal venous system and subsequent increase of effective blood volume. It stops variceal rebleeding and improves renal function. (7) The clinical stratification of patients
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receiving TIPS has been investigated in several studies, selecting either high-risk patients receiving TIPS for variceal bleeding (4) or patients with a lower risk receiving TIPS for refractory ascites and hepatorenal syndrome. (7) However, while the indication for TIPS might be one of the above, many patients present with other complications of portal hypertension and acute decompensation (AD) of liver cirrhosis. (8) Therefore, other predictors at TIPS insertion and at short-term clinical follow-up are needed to improve the disease management in these patients. (7) Liver stiffness, measured by either transient elastography (TE)-recently approved by the Food and Drug Administration in the United States-or shear wave elastography (SWE), is a useful parameter in the diagnosis of clinically significant portal hypertension and varices requiring treatment. (9) (10) (11) (12) (13) (14) (15) While it has been shown that liver and spleen stiffness might detect changes in hepatic venous pressure gradient after nonselective beta-blockers, the data were not as conclusive after TIPS. (16) (17) (18) (19) Importantly, a larger recent study could not sufficiently explain the reason behind the change of liver stiffness after TIPS. (20) This is probably due to the fact that liver stiffness is a result of various different factors, especially blood (arterial and venous) pressure, inflammation, and fibrosis. (21) (22) (23) The aim of this prospective observational cohort study, carried out in two centers, was to evaluate the change in liver and spleen stiffness measurement after TIPS as a parameter to stratify and follow up patients.
Patients and Methods

PATIENTS
This prospective observational cohort study was carried out in two centers and included patients with the following criteria: (1) reliable SWE or TE measurement of the liver before TIPS insertion and (2) feasible TIPS insertion. Exclusion criteria were (1) contraindication for TIPS (including diastolic dysfunction), (2) no reliable SWE/TE measurement, and (3) patient refusal or noncompliance.
Between April 2013 and November 2015, 128 patients were screened at the Department of Internal Medicine I of the University Hospital Bonn, Germany, and at the Department of Gastroenterology, University Hospital Freiburg, Freiburg, Germany. Of these, 83 patients were enrolled, while 45 patients did not fulfill the inclusion criteria (Fig. 1) . In 16 patients (acute group), liver stiffness was measured by TE immediately before and 30 minutes after TIPS insertion to detect acute changes. In 67 patients (chronic group), liver and spleen SWE was performed 1 day before and 7 days after TIPS insertion to detect chronic changes. Blood samples from portal, liver, and cubital veins were collected at TIPS insertion in 45 patients of the chronic group. The chronic group was followed in detail regarding short-term (median 7 days) and long-term follow-up. The study was registered after completion at clinicaltrials.gov (NCT03072615). All authors had access and were able to review and approve the final manuscript.
Within the context of another study, an additional 7 patients received TE and SWE of the liver before, 30 minutes after, and 7 days after TIPS.
ETHICS CONSIDERATION
Patients gave signed written informed consent for the procedures of the study. The local ethics committees of the Universities of Bonn (no. 121/14) and Freiburg (S-384/2009) approved the study in accordance with the Declaration of Helsinki.
TE PROCEDURE
Liver stiffness measurements using TE were performed immediately before and 30 minutes after TIPS insertion after fasting for at least 8 hours. TE measurement was performed as described. (24) (25) (26) In this study, only procedures with at least 10 valid shots, a success rate of at least 80%, and ratio of interquartile range and median <0.3 were considered reliable and used for statistical analysis. (24) (25) (26) The XL probe was used in patients with ascites according to earlier reports. (27) Nevertheless, all patients received paracentesis before TIPS and usually a drain catheter during hospitalization. Therefore, TE or SWE measurements were not influenced by ascites.
SWE PROCEDURE
Only accurate SWE measurements were performed after overnight fasting and considered and performed as described. (13, 14) An accurate SWE measurement showed (1) stability of the selected liver area for at least 3 seconds before measurement, (2) two-dimensional quality confirmed by homogenous color in the region of interest, and (3) a measurement region of at least 10 mm. Up to three separate measurements were performed, and results are reported as the mean of the total number of valid measurements. An increase or decrease in stiffness was regarded only if SWE measurement changed >10% because this was the variance within measurements applied in the same patients in previous studies. (13, 14) 
MEASUREMENTS OF PROINFLAMMATORY PROTEINS
During the TIPS procedure, to determine levels of different inflammatory proteins, first blood from cubital, then hepatic veins were collected, finally as soon as the portal vein branch was cannulated the portal venous sample was collected as well, as described. (28) (29) (30) (31) (32) In these patients and in 42 healthy controls, we measured interleukin 1beta (IL1b), IL6, and IL8 in the cubital vein using an enzyme-linked immunosorbent assay according to the manufacturer's guidelines (R&D Systems Inc., Minneapolis, MN).
Additionally, in 20 patients selected regarding their evolution of liver stiffness, samples taken from the cubital, liver, and portal veins of IL1b, IL6, IL8, IL10, IL18, and interferon-gamma were measured using the Luminex MAGPIX system (EMD Millipore, Darmstadt, Germany) with ProcartaPlex Mix&Match Human 15-plex (eBiosciences, Carlsbad, CA) according to the manufacturer's instructions.
TIPS INSERTION AND PRESSURE MEASUREMENT
TIPS (8 mm and 10 mm, Viatorr; W. L. Gore & Associates, Inc., AZ) insertion was performed as described. (6, (28) (29) (30) (31) (32) (33) Portal and inferior cava venous pressures were measured invasively using a multichannel monitor (Sirecust; Siemens, Germany). The difference between these pressures was defined as the pressure gradient.
FIG. 1.
Recruitment and study design. The flowchart illustrates screening and recruitment of the patients. In the acute group (recruitment in Freiburg), patients received liver stiffness measurements using TE immediately before TIPS and 30 minutes after TIPS. In the chronic group of patients (recruitment in Bonn), liver and spleen SWE was performed 1 day before TIPS and 7 days, 6 weeks, and 3 months after TIPS. Patients were followed for a maximum of 2 years. Abbreviations: HCC, hepatocellular carcinoma; HE, hepatic encephalopathy.
STATISTICAL ANALYSIS
A nonparametric Wilcoxon test was used to compare two sets of paired data. In addition, a Friedman test was used for more than two sets of paired data. A Mann-Whitney test was used for unpaired comparisons and a Kruskal-Wallis test if more than two groups were compared. Correlations were analyzed with Spearman's correlation coefficient. Univariate time-toevent analysis was performed to identify parameters which might significantly predict survival. Cox regression analysis (forward stepwise likelihood quotient) using the significant predictors in the univariate analysis was performed to identify independent predictors of survival. Kaplan-Meier curves were used to analyze the survival rates of patients using a log-rank test. Data are presented as median and ranges unless otherwise declared. P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL) and Prism 4.0 to plot a part of the graphs.
Results
RECRUITMENT AND GENERAL CHARACTERISTICS OF THE COHORT
In total, 128 patients were screened, of whom 45 were excluded. Seventeen patients had contraindications for TIPS: in eight cases, this was due to hepatocellular carcinoma and in nine cases, to severe overt hepatic encephalopathy. Twenty patients were excluded for noncompliance to the protocol, and in eight patients, no reliable SWE could be obtained due to obesity (Fig. 1) . Thus, 83 patients were included in the study, 16 patients received in Freiburg the acute protocol using TE and 67 patients received in Bonn the chronic protocol using SWE. Of these, 16 patients were included in the acute group receiving TE measurement of the liver immediately before and 30 minutes after TIPS and 67 patients were included in the chronic group receiving SWE of the liver and spleen 1 day before and 7 days after TIPS (Fig. 1 ). The latter group was followed for a maximum of 24 months.
The general characteristics of the cohort and of the acute and the chronic groups are outlined in Table 1 and Supporting Tables S1 and S2. Most of the included patients were male (61.4%), with a median age of 60 years. Of these patients, 64% suffered from alcoholic liver cirrhosis, 13% from chronic viral hepatitis, and 23% from other etiologies. In the whole cohort, median Child score was 8 and median Model for End-Stage Liver Disease (MELD) score was 9 ( Table 1) . Median Chronic Liver Failure Consortium (CLIF-C) AD score was 45.6, while median CLIF-C ACLF score was 35 (Supporting Table S2 ). No major differences were found between the acute and the chronic groups, except for a higher MELD score in the acute group (Table 1) .
ACUTE EFFECT OF TIPS ON LIVER STIFFNESS
In the acute group, liver stiffness was measured using the XL probe, which is validated for patients with ascites. In this group, TIPS decreased overall liver 
FIG. 2.
Effect of TIPS on acute and chronic changes of liver stiffness and chronic changes in spleen stiffness. In the acute group, liver TE showed a nonsignificant trend toward decrease in liver stiffness 30 minutes after TIPS (A). In two thirds of the patients from the acute group, liver stiffness significantly decreased (B), while in one third of the patients, liver TE increased without reaching significance (C). In the chronic group, liver and spleen SWE decreased 7 days after TIPS (D). Similarly, two groups of patients could be identified: patients with a decrease in liver SWE and spleen SWE after TIPS (E) and patients with an increase in liver SWE while spleen SWE decreased (F). Data are shown as mean and were analyzed using paired nonparametric comparisons with the Wilcoxon test. Mean values are available in the Supporting Table S3 , and individual data are available upon request. *P < 0.05 versus before TIPS.
JANSEN, M € OLLER, ET AL. HEPATOLOGY, April 2018
stiffness measured by TE, although without statistical significance ( Fig. 2A ; Supporting Table S3A ). Interestingly, in 11 patients a significant decrease of TE ( Fig.  2B ; Supporting Table S3A ) and in 5 patients an increase of TE ( Fig. 2C ; Supporting Table S3A ) was found. In these two different groups of patients, no significant changes were observed at baseline, except for a tendency to higher bilirubin, international normalized ratio, alanine aminotransferase, aspartate aminotransferase, and total white blood cell count (TWBC) in the group with increase in liver stiffness after TIPS (Supporting Table S1 ).
A recent series of 7 patients received TE and SWE of the liver before, 30 minutes after, and 7 days after TIPS within a context of another study. Importantly, 30 minutes after TIPS, liver SWE and TE values remained unchanged on day 7 after TIPS (data not shown).
EFFECT OF TIPS ON LIVER AND SPLEEN STIFFNESS AFTER 7 DAYS
In the chronic group, reliable liver SWE measurements were obtained in 67 patients and reliable spleen SWE measurements could be documented in 62 patients.
Liver and spleen stiffness measured by SWE decreased significantly after 7 days ( Fig. 2D ; Supporting Table S3B ). Similar to the acute group, in these patients, two different groups could be distinguished. There were 45 patients with a decrease or a change in liver SWE of <10% ( Fig. 2E ; Supporting Table S3B ) because this was the variance within measurements in the same patients in previous studies. (13, 14) These patients also showed a significant decrease in spleen SWE ( Fig. 2E ; Supporting Table S3B), whereas 22 patients showed an increase of >10% in liver SWE 7 days after TIPS and at the same time a significant decrease in spleen SWE ( Fig. 2F ; Supporting Table S3B ).
Comparing the baseline data of these two groups receiving SWE, no difference was found except for a tendency toward higher CLIF-C AD score, CLIF-C ACLF score, alanine aminotransferase, and C-reactive protein (CRP) but lower Child-Pugh score, MELD score, bilirubin, aspartate aminotransferase, gammaglutamyltransferase, TWBC, and pressure gradient (Table 2 ). However, none of these parameters were statistically significant, except for pressure gradient 3 . Levels of inflammatory cytokines in samples of cubital, portal, and hepatic vein blood collected at TIPS. IL1b levels in the cubital vein were higher in the group with increased liver SWE after TIPS (n 5 15) compared to the rest of the patients (n 5 39) and healthy controls (n 5 42), while all patients with cirrhosis showed higher levels than healthy controls (A). Similarly, IL6 and IL8 in (B) as well as IL18 and interferon-gamma in (C) showed higher levels in the group with increased liver SWE after TIPS (n 5 9) compared to the rest of the patients (n 5 11). Comparing levels of IL1b and IL18 in the portal and hepatic veins reveals similar results to findings from peripheral blood (D). Interestingly, intraindividual differences of IL1b, IL6, and IL10 between the levels found in the hepatic and portal veins were higher in the group with increased liver SWE after TIPS (n 5 9) compared to the rest of the patients (n 5 11) (E). Similarly, the difference between hepatic and portal venous levels of IL18 and interferon-gamma was also higher in the high-risk group (F). Data are shown as mean and standard error of mean, and comparison between groups was performed using the nonparametric Mann-Whitney U test. *P < 0.05, # P < 0.1. Abbreviation: INF, interferon-gamma.
before TIPS. In summary, the baseline clinical and laboratory parameters of the entire cohort revealed no statistically significant differences (Supporting Table  S2 ). Also, the stent diameter had no effect on development of liver SWE. Importantly, development of liver SWE was similar for the different indications for TIPS. Therefore, the cohorts of different indications were analyzed together.
INFLAMMATORY MARKERS BEFORE TIPS AND RESPONSE OF LIVER SWE TO TIPS
Yet, it remains unclear as to why liver stiffness might increase in around one third of the patients after TIPS, despite portal pressure decreases of >50%, which is reflected by a decrease in spleen SWE ( Fig. 2F ; Supporting Table S3B ).
To address this question, levels of proinflammatory cytokines were measured in peripheral blood samples of these patients. Interestingly, IL1b was significantly higher in the group with increased liver SWE when compared to the other patients. As expected, patients with cirrhosis showed higher levels of IL1b compared to controls (Fig. 3A) . Similarly, peripheral blood levels of IL6, IL8, IL18, and interferon-gamma were also higher in patients with an increase in liver SWE after TIPS (Fig. 3B,C) . These data suggest that systemic inflammation is already increased at TIPS insertion in patients who develop an increased liver SWE after TIPS.
However, the source of this systemic proinflammatory situation remains unclear. To address this question, cytokine levels were measured in the portal and hepatic veins. Interestingly, only IL1b and IL18 showed higher levels in the portal and hepatic veins in the group of patients with an increase in liver SWE after TIPS (Fig. 3D) . However, comparison of the difference in the levels of each cytokine between the hepatic and portal veins revealed a significant difference between the groups (Fig. 3E,F) . The gradient of proinflammatory cytokines IL1b, IL6, IL10, IL18, and interferon-gamma across the liver (levels in the hepatic veins were higher than in the portal veins) was significantly higher in patients with increased liver SWE after TIPS (Fig. 3E,F) . These data suggest that in these patients the liver has already reached a strong proinflammatory situation, as reflected in the higher levels of systemic inflammation measured in the peripheral blood samples (Fig. 3A-C) , but without, as yet, evidence in clinical and laboratory values ( Table 2) .
SHORT-TERM CLINICAL EVOLUTION AFTER TIPS AND RESPONSE OF LIVER SWE TO TIPS
Although all patients experienced a similar decrease in portal pressure gradient after TIPS (Table 2) , patients with an increase of liver SWE after TIPS seem to develop increased systemic and hepatic inflammation at TIPS insertion. Therefore, the outcome after TIPS was observed in more detail ( Table 2) .
Patients with decreased or unchanged liver SWE after TIPS showed a significant improvement in Child-Pugh score and creatinine, while liver function tests deteriorated significantly and MELD, CLIF-C AD, and CLIF-C ACLF scores, as well as TWBC and CRP, remained unchanged (Table 2) . By contrast, patients with an increase in liver SWE after TIPS showed significantly higher MELD, CLIF-C AD, and CLIF-C ACLF scores, as well as higher levels of alanine aminotransferase, aspartate aminotransferase, CRP, and TWBC ( Table 2 ). The latter patients showed no signs of congestions (heart failure) or hepatic ischemia. Moreover, while ascites disappeared in a considerable proportion of the patients with decreased or unchanged liver SWE after TIPS, the response to TIPS was significantly less in patients with an increased liver SWE after TIPS (Fig. 4A) . These data suggest that increased liver SWE after TIPS is associated with an inflammatory response mainly of hepatic origin, preventing clinical improvement in these patients after TIPS.
DEVELOPMENT OF ORGAN FAILURE AND LONG-TERM SURVIVAL AFTER TIPS
Because systemic inflammation is a hallmark of the development of organ failure and ultimately ACLF in liver cirrhosis, the incidence of organ failure was assessed 6 months after TIPS (Fig. 4B) . Indeed, there was a significantly higher incidence of organ failure in patients with an increase in liver SWE after TIPS (Fig. 4B) . Moreover, 2-year survival was significantly worse in patients with an increase in liver SWE after TIPS (Fig. 4C) . None of the patients has been transplanted.
When analyzing the parameters associated with survival in these patients, decreased or unchanged liver SWE 7 days after TIPS correlated significantly (hazard ratio [HR], 0.064; 95% confidence interval [CI], 0.007-0.547; P 5 0.012) with survival (Table 3) . Further parameters, such as age, CLIF-C AD score, creatinine 7 days after TIPS, as well as CRP 7 days after TIPS were identified as predictors of survival in univariate time-to-event analysis (Table 3) , while small liver size, low platelet count, and low hemoglobin levels were not significantly associated with survival in this cohort. Importantly, the MELD score showed an   FIG. 4 . Outcome of the patients in the follow-up. Among patients with increased liver SWE after TIPS, response of ascites to TIPS occurred in only 20% of patients compared to 60% of patients in the group with decreased or unchanged liver SWE after TIPS (A). Incidence of organ failure after 6 months was significantly higher in the high-risk group, as shown by Kaplan-Meier plot and analyzed by log-rank test (B). Importantly, the overall survival rate was unimpaired in patients with decreased or unchanged liver SWE after TIPS, while mortality was increased in patients with increased liver SWE after TIPS, as shown by Kaplan-Meier plot and analyzed by log-rank test (C).
HR of 1.001 with a 95% CI of 0.83-1.19 and a P value of 0.58. Therefore, the MELD score was also not included in the multivariate analysis.
Multivariable Cox regression analysis of these significant variables identified CRP (HR, 1.044; 95% CI, 1.004-1.084; P 5 0.03) and decreased or unchanged liver SWE (HR, 0.079; 95% CI, 0.009-0.690; P 5 0.022), both 7 days after TIPS, as independent predictors of survival (Table 3) .
Discussion
This prospective observational cohort study demonstrates that liver stiffness after TIPS is a stratification tool for high-risk patients. Moreover, this study possibly explains the increase of liver stiffness after TIPS in some patients, while it also confirms the important role of hepatically derived systemic inflammation in the outcome of patients with decompensated cirrhosis.
Liver stiffness has been introduced in the field of digestive diseases to identify significant liver fibrosis. (26) Liver stiffness assessed by TE (9) (10) (11) 24, 26, 34, 35) or SWE (12, 36) might identify clinically significant portal hypertension. However, liver TE and SWE very much depend on other factors, such as alcohol and meal ingestion, right heart function, volume changes, arterial pressure, cholestasis, and inflammation. (22, 23, (37) (38) (39) (40) (41) (42) While TIPS decreased portal pressure by >50%, liver stiffness was not proportionally decreased, as assessed by two different techniques of measuring liver stiffness, at different time points after TIPS and in different centers. In a similar portion of patients, liver stiffness increased after TIPS, regardless of TIPS indication or diameter.
Moreover, the present study defines the prognostic impact of an increase in liver stiffness after TIPS. These patients could only be identified by the increase of liver stiffness after TIPS and not by any other clinical or routine laboratory parameters. The increase occurred very early after TIPS insertion, as shown in the acute cohort, and continued up to the next followup visit. This finding outperforms the MELD score for overall survival, which was designed for outcome assessment 3 months after TIPS. (43) The pathophysiological processes responsible for the deterioration of clinical outcome and increase in liver stiffness in this subgroup of patients receiving TIPS are insufficiently explored. Frequently, the opening of the route for portal venous blood into the systemic circulation by TIPS has been blamed for increased systemic inflammation in TIPS patients. The present study clearly demonstrates that systemic inflammation had already increased in these patients before TIPS, as shown by higher levels of IL1b, IL6, IL8, IL18, as well as interferon-gamma in peripheral blood. Moreover, levels of IL1b and IL18 were higher in the hepatic and portal veins of patients receiving TIPS. Interestingly, in patients who developed increased liver stiffness after TIPS and who had poor outcome, much higher inflammatory markers were found in the hepatic veins than in the portal veins. This suggests that the source of systemic inflammation in these patients is the diseased liver, while in patients who recovered after TIPS and who had a good prognosis, levels of inflammatory cytokines in the hepatic veins were lower than in the portal veins. Apart from the acute testing of liver stiffness in these patients, the difference between portal and hepatic levels of cytokines appears also to be fitting to distinguish between patients with better or worse prognosis. Especially the increase of IL6, which is a marker of systemic inflammation, seems to derive from the injury the liver had sustained already before TIPS insertion. IL6 has been shown to predict variceal bleeding as well as mortality in patients with ACLF. (2, 44) In this study, we suggest that it might derive from the immune cells of the injured liver. Moreover, at the next follow-up, systemic inflammation aggravated and was clinically evident, as shown by increases in CRP and TWBC. This was also mirrored by AD and ACLF scores, which predict the incidence of ACLF and survival. (45, 46) Recently, the close relationship between systemic inflammation, organ failure, ACLF, and mortality has been shown in the CANONIC cohort. (2) Indeed, the increase of liver stiffness after TIPS identified patients developing organ failure and independently predicted mortality in patients receiving TIPS, which is also supported by previous observations of our group ascribing an important prognostic value to inflammatory cytokines. (28) (29) (30) 32) However, it is difficult to predict whether patients with increased liver stiffness after TIPS would not have developed organ failure or ACLF and would not have shown a higher mortality without TIPS, a question to be addressed in future studies. Turning the argument around, TIPS might prevent ACLF in patients with decreased stiffness because portal hypertension is a predisposing factor for ACLF. (47) TIPS might prevent ACLF in several situations (7) ; e.g., early TIPS prevents the inflammatory response induced by further bleeding and improves survival. (4) Apart from these open questions, the present study demonstrates and offers an interesting and easy approach for the clinical routine to identify high-risk patients after TIPS.
Our data suggest that liver stiffness increases immediately after TIPS. Interestingly, these patients do not show higher stiffness before TIPS. Although liver stiffness might change after alcohol withdrawal (37) and correlates with liver damage, (48) the rather prompt change of liver stiffness only minutes after the TIPS procedure suggests pressure changes as the underlying cause. In general, liver stiffness measurement is an integrative measure of fibrosis, inflammation, and sinusoidal pressure. (21) (22) (23) In this system, TIPS might decrease the portal pressure and portal perfusion of the sinusoids but increase arterial perfusion of the sinusoids, (49) while in our patients, fibrosis and arterial pressures remained unchanged. The only difference between the groups of patients in whom liver stiffness increased after TIPS was the presence of hepatic and systemic inflammation. More importantly, it has recently been shown that systemic inflammation increases intrahepatic sinusoidal resistance. (50) Thus, to speculate, one is tempted to assume that challenge of the sinusoids with twice the hepatic arterial perfusion (49) might be the reason for the acute increase in stiffness after TIPS.
Another important finding of this study is that liver SWE is unsuitable to reflect changes in the portal pressure gradient in decompensated patients. Previous data have shown that liver TE or SWE possibly reflects the effect of nonselective beta-blockers (16, 17) and that SWE also excludes or includes with high accuracy the presence of clinically significant portal hypertension, (12, 17, 36) a prerequisite for decompensation, complications, and, ultimately, ACLF. (1, 7, 47) Recent studies have suggested that spleen SWE is very important for the diagnosis of portal hypertension and changes in portal pressure. (13, 14, 19, 20) Indeed, our study might provide an explanation for these findings.
Despite the fact that our study is a prospective observational study carried out in two centers, with two different well-characterized patient cohorts at two different time points, several limitations must be mentioned. First, this is an observational study, and due to its exploratory nature, it lacks a clear hypothesis and sample size calculation. Although we used the XL probe for TE, which has been validated for ascites, this may be cause for some criticism regarding reliability. Although in the patients of this study, we could not provide data of TE and SWE from the same patients at the same time points, within the context of another study, we recently performed a small series of 7 patients with SWE and TE of the liver at the same time, before, 30 minutes after, and 7 days after TIPS. Another limitation is that in the smaller TE group, no follow-up data were collected because this was an acute study. However, recently, together with others, we found very similar results in the TE and the SWE response to different challenges to the portal venous system. (38) Therefore, we assume that this is also the case in the present study. A further limitation is the rather small size of the cohort. However, this is the largest cohort in patients with TIPS. Despite the rather small group of patients, our study demonstrated high examiner independency because at two different sites, using two different techniques at different time points to measure liver stiffness, the results were very similar. Finally, because post-TIPS SWE change is a marker of poor prognosis after TIPS, it is not helpful to select patients before TIPS. However, it might be helpful for risk stratification in patients receiving TIPS because they will receive TIPS for a clear indication unrelated to SWE. Moreover, the measurement of systemic inflammation, as demonstrated in our cohort, might be useful to stratify patients before TIPS insertion.
In conclusion, this study demonstrates that it is mainly liver-derived systemic inflammation that predisposes patients receiving TIPS to develop organ failure and ACLF. These patients show an increased liver stiffness after TIPS immediately and at follow-up.
Therefore, inflammation at TIPS insertion and increase of liver stiffness after TIPS insertion predict organ failure and death in these patients, who require closer management.
